■基底细胞癌(BCC)是全球最常见的癌症类型。虽然BCC的治疗有几种治疗选择,选择眶周BCC的最佳治疗方案具有挑战性,并且因病例而异。超过一半的眼周BCC病例最初发生在内角和下眼睑。BCC的治疗选择包括使用Mohs显微成像技术进行根治性手术切除,放射治疗,新辅助药物vismodegib,咪喹莫特,和联合治疗,然后重建功能和美学结果。每种治疗的选择根据BCC的严重程度和扩展而变化。
我们报告了一名50岁的高加索男性的眶周BCC侵入左下眼睑的病例,该病例最初是几年前切除的,and,复发后,患者接受了Mohs显微手术.由于Mohs显微手术后复发,开始口服vismodegib治疗,导致肿瘤几乎完全缩小。为了确定使用vismodegib治疗的眶周BCC的结果,我们回顾了用vismodegib治疗眶周BCC的文献,他们的随访期,结果,以及它们是否转移或复发。
■新佐剂vismodegib,然后是手术切除,比如Mohs显微外科手术,在眶周BCC的治疗中显示出有希望的临床和美学结果。
UNASSIGNED: Basal cell carcinoma (BCC) is the most common cancer type worldwide. Although there are several treatment options for the treatment of BCC, selecting the best treatment option for periorbital BCC is challenging and it varies case by case. More than half of periocular BCC cases initially occur on the inner angle and lower lid. The treatment options for BCC include radical surgical excision using Mohs micrographic technique, radiotherapy, neoadjuvant vismodegib, imiquimod, and combination therapy followed by reconstruction for functionality and aesthetic outcome. Selection of each treatment varies based on the severity and extension of BCC.
UNASSIGNED: We report a case of periorbital BCC invading the left lower eyelid in a 50-year-old Caucasian male which was initially excised a few years ago, and, following recurrence, the patient underwent Mohs micrographic surgery. Due to a recurrence after Mohs micrographic surgery, treatment with oral vismodegib was started, which led to near-total tumor shrinkage. To determine the outcome of periorbital BCC treated with vismodegib, we reviewed the literature on the periorbital BCC treated with vismodegib, their follow-up period, outcome, and whether they were metastatic or had recurrence.
UNASSIGNED: Neoadjuvant vismodegib, followed by surgery excision, such as Mohs micrographic surgery, has shown a promising clinical and aesthetic outcome in the treatment of periorbital BCC.